IN8bio: Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

 

• Durable complete remission (CR) achieved in 100% of treated patients, including high-risk and relapsed acute myeloid leukemia (AML) patients and those who had failed multiple prior lines of therapy, including CAR-T.
  
  
• All trial participants remain alive and relapse free as of last assessment, and six patients have been relapse free for over one year.
  
  
• New data shows long-term in-vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration of INB-100, demonstrating the first-ever durable persistence of an allogeneic cellular therapy.
  
  
• Data to be presented today (abstract: 4853) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
  
  
• The Company will host a conference call at 8:30 am ET tomorrow to discuss these updates. Please use this link to participate in the live call; a listen-only version of the webcast is available here.

https://www.globenewswire.com/news-release/2023/12/11/2794257/0/en/IN8bio-Announces-Positive-Clinical-Update-Demonstrating-Continued-Durable-Complete-Remission-in-100-of-Evaluable-Patients-in-Phase-1-Trial-of-INB-100-in-Leukemia.html